23andMe Holding Co. (ME)

USD 3.14

(-3.09%)

Market Cap (In USD)

85.82 Million

Revenue (In USD)

219.63 Million

Net Income (In USD)

-666.7 Million

Avg. Volume

3.37 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.655-19.34
PE
-
EPS
-
Beta Value
1.261
ISIN
US90138Q1085
CUSIP
90138Q108
CIK
1804591
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Ms. Anne Wojcicki
Employee Count
-
Website
https://www.23andme.com
Ipo Date
2020-11-23
Details
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.